Publications
5891 Results
- Journal / Conference
- The Oncologist 17(2):179-187;
- Year
- 2012
- Research Committee(s)
- Breast
- PMID
- PMID22267853
- PMC
- PMC3286166
- Study Number(s)
- S0430
Phase II trial of simple oral therapy with capecitabine and cyclophosphamide in patients with metastatic breast cancer: SWOG S0430 [PMID22267853]
- Journal / Conference
- European Urology, 61(6):1263-1270;
- Year
- 2012
- Research Committee(s)
- Cancer Control
- PMID
- PMID22459892
- PMC
- PMC4059403
- Study Number(s)
- SWOG-9217
Finasteride reduces the risk of incident symptomatic benign prostatic hyperplasia
- Journal / Conference
- Journal of the National Cancer Institute 104(18):1373-1385;
- Year
- 2012
- Research Committee(s)
- Cancer Control
- PMID
- PMID22972968
- PMC
- PMC3529595
- Study Number(s)
- SWOG-9217
Health-related quality of life findings for the Prostate Cancer Prevention Trial
- Journal / Conference
- Journal of Urology 187(6):2005-2010;
- Year
- 2012
- Research Committee(s)
- Prevention, Screening, and and Surveillance
- PMID
- PMID22498220
- PMC
- PMC4294531
- Study Number(s)
- S0000
Evaluation of selenium supplementation on the prevention of bladder cancer in SWOG-coordinated SELECT
- Journal / Conference
- Medical Care 50(5):388-393;
- Year
- 2012
- Research Committee(s)
- Breast
- PMID
- PMID22274803
- PMC
- PMC3469160
- Study Number(s)
- S1007
Prioritization in comparative effectiveness research: the CANCERGEN experience in cancer genomics
- Journal / Conference
- Journal of Thoracic Oncology 7(5):906-992;
- Year
- 2012
- Research Committee(s)
- Gastrointestinal
- PMID
- PMID22481235
- PMC
- PMC3382003
- Study Number(s)
- S0414
Cetuximab plus cisplatin, irinotecan, and thoracic radiotherapy as definitive treatment for locally advanced, unresectable esophageal cancer: a phase II study of the SWOG (S0414)
- Journal / Conference
- Medical Oncology 29(2):761-767
- Year
- 2012
- Research Committee(s)
- Genitourinary
- PMID
- PMID21298497
- PMC
- PMC3566570
- Study Number(s)
- CTSU/E8802
A phase II trial of doxorubicin and gemcitabine in renal cell carcinoma with sarcomatoid features: ECOG 8802
- Journal / Conference
- Journal of Clinical Oncology 30(suppl 4; abstr 198); ASCO 2012 GI Cancers Symposium, poster;
- Year
- 2012
- Research Committee(s)
- Gastrointestinal
- Study Number(s)
- S0727
Phase I and randomized phase II trial of gemcitabine, erlotinib, and IMC-A12 (cixutumumab) versus gemcitabine plus erlotinib as first line treatment in patients with metastatic pancreatic cancer (SWOG-0727)
- Journal / Conference
- Journal of Clinical Oncology 30(supl 4; abstr 203); ASCO 2012 GI Cancers Symposium, poster presentation;
- Year
- 2012
- Research Committee(s)
- Gastrointestinal
- Study Number(s)
- S0205
Use of EGF A61G polymorphism predicts overall survival in a phase III study of gemcitabine plus cetuximab versus gemcitabine in patients (pts) with locally advanced or metastatic pancreatic adenocarcinoma (SWOG 0205)
- Journal / Conference
- Clinical Cancer Research 18(4):1129-1137;
- Year
- 2012
- Research Committee(s)
- Melanoma
- PMID
- PMID22228638
- PMC
- PMC3481165
- Study Number(s)
- S0438